2022
DOI: 10.1007/s12265-022-10301-5
|View full text |Cite
|
Sign up to set email alerts
|

Identification of Gravida Serum Biomarkers for Noninvasive Prenatal Diagnosis Fetal Congenital Heart Disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

1
1
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
1
1

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 27 publications
1
1
0
Order By: Relevance
“…However, due to the lack of clinical data, further research is needed to explore its potential as a new cardiac biomarker [ 12 ]. Nonetheless, our findings not only further support the potential of POSTN as a new cardiac disease biomarker but also validate the reliability of our previous proteomic results [ 10 ].…”
Section: Discussionsupporting
confidence: 90%
“…However, due to the lack of clinical data, further research is needed to explore its potential as a new cardiac biomarker [ 12 ]. Nonetheless, our findings not only further support the potential of POSTN as a new cardiac disease biomarker but also validate the reliability of our previous proteomic results [ 10 ].…”
Section: Discussionsupporting
confidence: 90%
“…It belongs to the family of IFN-induced proteins that have a wide range of antiviral functions and have been studied mainly in RNA viruses [4]. POSTN encodes a secreted extracellular matrix protein that functions in tissue development and regeneration, including wound healing, and ventricular remodeling following myocardial infarction [33]. THBS1 encodes an adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix interactions.…”
Section: Discussionmentioning
confidence: 99%